Infectious disease
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
The U.S. government is putting together the infrastructure for widespread distribution of a COVID-19 vaccine, if and when one is granted emergency use authorization (EUA) or full approval.
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
NanoViricides, based in Shelton, Connecticut, outlined its approach to developing therapies against COVID-19 at the LD 500 investor conference yesterday.
As we head into cold and flu season, the question arises: Can you get COVID-19 and the flu at the same time?
Researchers at San Francisco’s Gladstone Institutes published research on bioRxiv—which means it has not been peer-reviewed—that demonstrated, in culture, how the virus damages cardiac muscles.
When Moncef Slaoui was tapped to helm Operation Warp Speed, he sought confirmation that politics would not play a role in driving certain treatments through an approval process without the proper supporting scientific data to back it up.
It’s entirely possible that what we will be seeing most from the U.S. Food and Drug Administration for the month of September is related to treatments and vaccines for COVID-19.
Treatments for COVID-19 may be focusing on at the wrong elements of the disease, according to physicians analyzing results from Bergamo, Italy, the epicenter of the pandemic in Europe.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.
PRESS RELEASES